Vertex begins Phase II development programme for VX-950 (Hep C)

Vertex begins Phase II development programme for VX-950
InPharm.com - an investigational oral hepatitis C (HCV) protease inhibitor for the treatment of HCV infection. The 28-day

InterMune, Inc. (ITMN) Announces Clinical Data Presented At AASLD That Support Phase III DIRECT Trial For HCV
BioSpace - Announces Clinical Data Presented At AASLD That Support Phase III DIRECT Trial For HCV SAN FRANCISCO, Nov infected with hepatitis C virus (HCV) who failed to adequately respond to

HCV Protease VX950 Study Starts
National AIDS Treatment Advocacy Project - Health Medical _